Pharvaris (NASDAQ:PHVS) Coverage Initiated by Analysts at Wolfe Research

Key Points

• Wolfe Research initiated coverage on Pharvaris with an "Outperform" rating and a $42 price target, implying roughly a 52% upside from the current share price.
• The analyst consensus is a Moderate Buy (11 Buys, 2 Holds, 1 Sell) with an average target of $42.73, though some firms (e.g., HC Wainwright) have much higher long-term targets while others maintain sell ratings.
• Pharvaris is a clinical‑stage biotech advancing PHA121, an oral plasma kallikrein inhibitor for hereditary angioedema; shares trade around $27.56 (market cap ≈ $1.5B) and major investors like General Atlantic hold sizable positions.

Wolfe Research assumed coverage on shares of Pharvaris (NASDAQ:PHVS - Get Free Report) in a report issued on Thursday. The brokerage set an "outperform" rating and a $42.00 price target on the stock. Wolfe Research's price target indicates a potential upside of 52.39% from the company's current price.

A number of other analysts have also recently weighed in on the stock. Royal Bank Of Canada reduced their target price on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a report on Monday. Wedbush raised their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday. Wall Street Zen cut Pharvaris from a "hold" rating to a "sell" rating in a report on Sunday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Pharvaris currently has an average rating of "Moderate Buy" and a consensus target price of $42.73.

Pharvaris Price Performance

Shares of PHVS opened at $27.56 on Thursday. The firm's 50 day moving average is $27.07 and its 200-day moving average is $25.50. The stock has a market capitalization of $1.50 billion, a P/E ratio of -8.18 and a beta of -2.58. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.85.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL acquired a new position in Pharvaris in the 3rd quarter valued at approximately $1,943,000. TFG Asset Management GP Ltd grew its holdings in shares of Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock valued at $3,311,000 after acquiring an additional 61,105 shares in the last quarter. Boothbay Fund Management LLC grew its holdings in shares of Pharvaris by 735.1% during the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company's stock valued at $3,373,000 after acquiring an additional 118,994 shares in the last quarter. General Atlantic L.P. increased its stake in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock worth $200,380,000 after acquiring an additional 500,000 shares during the last quarter. Finally, Patient Square Capital LP increased its stake in shares of Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company's stock worth $8,617,000 after acquiring an additional 101,098 shares during the last quarter.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target on PHVS to $42 and kept an "outperform" rating, implying roughly a 50%+ upside from the stock's recent level — a clear catalyst for buying interest. Read More.
• Positive Sentiment: HC Wainwright published a long-term bullish forecast, projecting FY2030 EPS of $5.37 and maintaining a "Buy" rating with a $60 price target — reinforcing upside expectations well above current levels. Read More.
• Positive Sentiment: HC Wainwright also lifted multiple multi-year earnings estimates (FY2027–FY2029/FY2030) and nudged FY2026 expectations slightly higher overall, signaling analyst confidence in Pharvaris’ longer-term revenue/earnings trajectory. This supports higher price-target revisions by other firms. Read More.
• Neutral Sentiment: HC Wainwright made mixed near-term adjustments: modest downward tweaks to Q1 and Q2 2026 EPS (e.g., Q1 to ($0.83) from ($0.80), Q2 to ($0.89) from ($0.87)) while slightly raising Q3/Q4 and later-year estimates — a mixed signal for short-term results but not a reversal of the bullish long-term call. Read More.
• Negative Sentiment: Royal Bank of Canada issued a pessimistic forecast for PHVS, which could temper upside momentum or trigger short-term selling by more conservative investors. Read More.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.